MedPath

Therapeutic drug monitoring of mycophenolic acid and validation of limited sampling strategies for the estimation area under the mycophenolic acid concentration-time curve in Thai pediatric renal transplant recipients at Siriraj hospital

Phase 1
Not yet recruiting
Conditions
evel of MPA in pediatric kidney transplantedInfection
Registration Number
TCTR20170206004
Lead Sponsor
Faculty of Medicine Siriraj Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
25
Inclusion Criteria

1. Renal transplant recipients who aged under 18 years old
2. Renal recipient who underwent transplantation for at least 3 months and follow-up at Siriraj hospital
3. Renal recipient who on stable dose of MPA (MMF or EC-MPS) for at least 1 week
4. Renal recipient who voluntarily given consent to participate the study by their parents or caregiver and additional assent for children 7-18 years old

Exclusion Criteria

1.Renal recipient who has hematological abnormalities within 3 months:
- Hemoglobin < 5 gm/dl, or
- Platelet < 100,000 cell/mm3
2.Renal recipient who has concomitant drug use which might change the PK properties of MPA such as omeprazole, metronidazole, norfloxacin, pantoprazole, rifampin, antacids, cholestyramine, rabeprazole, esomeprazole, lansoprazole, dexlansoprazole, colestipol, colesevelam, activated charcoal, cyclosporine
3.Renal recipient who has condition that affect PK od MPA such as gastrointestinal diseases, liver dysfunction

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mycophenolic acid area under concentration&#45;time curve 0&#44; 0.5&#44; 1&#44; 1.5&#44; 2&#44; 2.5&#44; 3&#44; 4&#44; 6&#44; 8&#44; 12 after dosng Plasma/ measure by UPLC/PDA
Secondary Outcome Measures
NameTimeMethod
imited sampling stategies&#44; pk parameters&#44; Adverse events &#45; Statistical analysis
© Copyright 2025. All Rights Reserved by MedPath